Who is Shantanu Narayen and why is his appointment significant?

Shantanu Narayen is being appointed to Pfizer's Board of Directors. While the 8-K doesn't detail his specific background, his appointment to the Board and its committees suggests his expertise will contribute to Pfizer's governance and strategic direction, particularly in areas of science and technology.

What is the financial impact of this board appointment on Pfizer?

The financial impact is minimal and related to standard compensation for non-employee directors. The 8-K specifies that Mr. Narayen will receive compensation according to Pfizer's usual arrangements for directors who are not company employees. This is a typical operational cost and not a significant financial event for the company.

Are there any other material changes or disclosures in this 8-K filing?

No, this 8-K filing is primarily focused on the appointment of Shantanu Narayen to the Board of Directors and his committee assignments. There are no other material financial or operational disclosures mentioned in the filing itself, other than the incorporation by reference of the press release detailing this appointment.

PFE 8-K: Leadership Changes

Summary

Pfizer Inc. (PFE) filed an 8-K report on September 30, 2013, to announce a change within its Board of Directors. The most significant development is the election of Shantanu Narayen as a new member of the Board, effective September 27, 2013. Mr. Narayen's appointment also includes his roles on the Corporate Governance Committee and the Science and Technology Committee. Investors should note that Mr. Narayen will receive compensation according to Pfizer's standard practices for non-employee directors and has been provided with an indemnification agreement. The filing also references a press release dated September 30, 2013, which further details this board change and is incorporated by reference.

Key Highlights

1Pfizer Inc. elected Shantanu Narayen to its Board of Directors, effective September 27, 2013.
2Mr. Narayen has been appointed to the Corporate Governance Committee of the Board.
3Mr. Narayen has also been appointed to the Science and Technology Committee of the Board.
4Mr. Narayen will be compensated according to Pfizer's standard arrangements for non-employee directors.
5An indemnification agreement has been provided to Mr. Narayen.
6The filing includes a press release dated September 30, 2013, as an exhibit detailing the board appointment.
7This is a routine disclosure for a change in board composition.

PFIZER INC 8-K Report, Executive Changes (Sep 30, 2013)

Summary

Key Highlights

Frequently Asked Questions